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Abstract 
The delivery of human adult mesenchymal stem cells (hAMSC) using bone void 
fillers is a novel approach for use in bone tissue engineering.  The evaluation of hAMSC 
and osteoblast- like MG-63 cell activity on three b-tricalcium phosphate-based bone void 
fillers (VitossTM, ChronOSTM Granulat and ChronOSTM) has not been carried out.  Human 
osteosarcoma cells (MG-63 cells), as well as hAMSCs, readily seed over 90% of the 
available biomaterials under static culture conditions, and the attached cells proliferate to 
extensively cover the biomaterials as seen by DAPI staining and LIVE/DEAD viability 
staining.  The attached cells are over 90% viable after 7 days in culture as assessed by 
LIVE/DEAD staining.  CyQUANT assays show a statistically significant increase in cell 
proliferation over a 7 day culture period.  hAMSCs cultured in the presence of an 
osteogenic supplement on VitossTM and ChronOSTM show a statistically significant 
increase in alkaline phosphatase activity 14 days post-addition of osteogenic supplement.  
MG-63 cells also show increased alkaline phosphatase activity in response to an 
osteogenic supplement.  These biomaterials show promise for use as vehicles for cell 
delivery to place large numbers of cells directly into a wound site or onto a tissue-
engineering scaffold. These b-tricalcium phosphate-based bone void fillers are 
biocompatible and biodegradable as indicated by their clinical use.  These bone void 
fillers when seeded with human adult mesenchymal stem cells that differentiate into 
osteoblasts could possibly increase healing efficiency in bone defects. 
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INTRODUCTION 
 A large variety of bone substitutes are available for the treatment of congenital or 
acquired bone defects as an alternative to bone transplantation.  Generally, bone 
transplantation treatments rely either on autografts (grafts from patient), or allografts 
(grafts from cadavers).  The use of both autografts and allografts pose problems including 
adequate supply, risk of rejection, and disease (Laurencin et al., 1999).  Synthetic bone 
graft materials that are commercially available have not met clinical expectations.   
Multiple treatments exist for bone defects that do not heal on their own.  These 
include bone transplantation and reconstructive surgery, implantation of bone void fillers 
and supplementation with metabolic products.  Other methods used to regenerate bone 
include gene therapies, bone matrices, bone morphogenetic proteins (BMPs - proteins 
that modulate bone healing) and stem cell culture (Service, 2000).  Cell culture involves 
the isolation, proliferation and expansion ex vivo which includes culturing cells on a 
scaffold that acting as a supporting matrix.  In most cases the scaffold provides essential 
growth factors and nutrients to the cells allowing for bone regeneration.  Examples 
include alginate hydrogel scaffolds seeded with growth factors (BMP2 and a factor to 
induce cell phenotypic transformation, TGF-b3) and rat bone marrow progenitor cells to 
heal bone defects in SCID mice (Simmons et al., 2004).  Another example is the use of 
scaffolds of platelet rich plasma, cancellous bone and bone marrow seeded with in vitro 
expanded mesenchymal stem cells from dogs into autologous bone defects (Yamada et 
al., 2004).  Ceramics scaffolds such as calcium carbonate-based hydroxyapatite have 
been used to culture human osteosarcoma cells in an effort to estimate favorable 
porosities of the scaffold to aid in bone regeneration studies (Rose et al., 2004).      
  Bone scaffolds or matrix can be obtained from a range of substances such as 
demineralized and processed bone from cadavers or animals, synthetic materials such as 
coral hydroxyapatite, synthetic polymers and ceramics.  Scaffolds are meant to degrade 
over time and be replaced by regenerating new bone.  Annually, over 1.3 million bone 
trauma surgical procedures are carried out and of these, spinal non-unions account for 
56% of all procedures (Lee et al., 2004;Langer and Vacanti, 1993).  In 1996, bone graft 
procedures totaled approximately 500,000 in the United States.  The demands for these 
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procedures were met with 60% autografts, 34% allografts and 7% synthetic materials 
such as ceramics (Ishaug et al., 1994).  Autografts are perceived to be osteoconductive as 
they provide a scaffold structure and are osteoinductive as they provide factors that 
stimulate host bone tissues to colonize the graft and heal bone (Ishaug et al., 1994).  The 
benefits of autografts vs. allografts, as well as ceramics with their perceived shortcomings 
are presented in detail in later sections. 
The long-term goal of bone tissue engineering is to regenerate new, healthy bone 
in a patient.  The goal of my project was to determine whether synthetic, ceramic bone 
void filler materials would prove to be a useful tool in bone regenerative medicinal 
applications.  I assessed the attachment, proliferation, and differentiation capabilities of 
two osteoblastic cell types on three types of ceramics in vitro.  My research evaluated 
whether the ceramics VitossTM, ChronOSTM Granulat and ChronOSTM would be suitable 
candidates as scaffolds and carriers for possible implantation into bone defects. 
 
BACKGROUND 
 
Bone – A dynamically remodeled tissue 
 Bone can exist either as compact (cortical) or cancellous (spongy) bone in long 
bones.  Cortical bone is found mainly in the ‘length’ of long bones and defines an area 
called the diaphyses.  Cancellous bone, in contrast, is found mostly at the epiphyses of 
long bones, which are the ends.  Cancellous bone is spongy as it contains the bone 
marrow.  Yellow marrow is found at the center of bones within the medullary cavity and 
is used to store fats (Buckley, 2004;Bonnet, 2003).   
 The organic matrix in bone is primarily Type I collagen (95%) and the remaining 
percentage includes non-collagenous proteins and proteoglycans (Parfitt, 1994).  The 
collagen matrix is further strengthened by calcium phosphate in the form of 
hydroxyapatite.  This forms a crystalline lattice with the formula (Ca10(PO4)6 (Cohen-
Solal and de Vernejoul;Parfitt, 1994).  Mature osteocyte cells reside in this hard matrix in 
lacunar spaces.  New bone grows by a process termed apposition, which involves 
formation of new matrix and degradation of the older matrix.  This scales up the size of 
bone as well as continuously turns over the matrix (Cohen-Solal and de Vernejoul, 2003). 
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Cell types in living bone 
 Bone tissue in itself is composed of four different cell types: osteoblasts, 
osteoclasts, bone lining cells on the surfaces of bone, and osteocytes within the 
mineralized component (Rodan, 1992).   Osteoblasts lay down new bone while 
osteoclasts digest away old bone.  Osteocytes are mature osteoblasts contained in a 
calcified matrix are responsible for intercellular communication. The bone lining cells are 
considered to be fairly inactive carrying out neither absorption nor formation.  Little is 
known about their function but it is speculated that they could also be precursors for 
osteoblasts (Bilezikian et al., 1996).  For our purposes, a discussion of osteoblasts, 
osteoclasts and osteocytes follows, as they are most pertinent in studying the dynamics of 
bone formation and remodeling.     
 
The osteoprogenitor cell and the osteoblast lineage 
 Autoradiography using tritiated thymidine shows that osteoprogenitor cells are 
undifferentiated mesenchymal cells that are found in the stroma surrounding bone 
marrow (Majumdar et al., 1998).  Since these mesenchymal cells have the ability to 
develop into a number of different cell types and contribute to the regeneration of 
mesenchymal tissue such as bone, cartilage, adipose, tendon, ligament, muscle and 
stroma, they are multipotent adult progenitor cells (Lazarus et al., 1995).  These adult 
mesenchymal stem cells have been isolated from bone marrow that is taken from the iliac 
crest and expanded.  Studies have characterized these cells by their ability to proliferate 
in culture and they resemble a fibroblast- like morphology.  Upon isolation, these cells 
uniformly test positive for SH2, SH3, CD29, CD44, CD71, CD90, CD106, CD120a and 
CD124 and other surface proteins.  The cells test negative for CD34, a marker for the 
hematopoietic lineage.  The cells are able to maintain normal karyotypes and telomerase 
activity even at high passages (Pittenger et al., 1999).  
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Osteoblasts and mature osteocytes 
Osteoblasts are cells that lie at the surface of the bone matrix that is already 
formed and they deposit new matrix or osteoid.  They are fully differentiated cells. They 
lay down bone matrix, by secreting collagen Type I and other non-collagenous proteins 
(Mackie, 2003;Bilezikian et al., 1996).  The osteoblasts themselves often embed 
themselves in the new matrix that they form and are then termed osteocytes.  The matrix 
hardens as calcium phosphate (hydroxyapatite) crystals are deposited in it.  The osteocyte 
is considered to be the most terminally differentiated cell of the osteoblast lineage.  
Osteocytes are embedded in the bone matrix and communicate with other cells through 
gap junctions present in the canaliculi (Knothe Tate et al., 2004).   Before becoming 
trapped in the matrix, the osteocytes test posit ive for the presence of alkaline phosphatase 
activity, as functional mature osteoblasts (Knothe Tate et al., 2004).  These osteoblasts 
can also be identified by the other products they produce such as Type I collagen, 
osteopontin, osteonectin, osteocalcin and bone sialoprotein (Knothe Tate et al., 2004).  
Osteoblasts that are active show alkaline phosphatase (ALP) activity that can be detected 
with a histochemical stain (Abdallah et al., 2004;Justesen et al., 2002;Miao and Scutt, 
2002) and by a biochemical assay that can quantify enzyme activity (Wang et al., 
2003;Jaiswal et al., 1997) .   
 
Non-unions and critical sized bone defects 
 When bone healing is delayed, the healing might be a malunion (incorrect union) 
or the bone fails to heal completely.  Such non-unions are referred to as critical-sized 
defects.  There is a low frequency of union with bone grafts in human bone defects that 
are larger than or equal to 6 cm (Szpalski and Gunzburg, 2002).  Approximately 170,000 
fractures occur in the United States each year that are unable to heal on their own.  These 
critical-sized defects are treated by bridging with a scaffold which is osteoconductive and 
carries cells and growth factors into the defect site.   The presence of non-unions 
substantially lengthens the morbidity time of the patient due to the inconvenience and 
pain of a non-healing bone. 
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Bone healing and regenerative medicine 
The most common tissue for transplant procedures is bone tissue.  Out of the 
500,000 bone graft procedures per year, half relate to spinal surgeries (Linovitz and 
Peppers, 2002).  Synthetic materials are man-made materials such as metals, plastic or 
ceramics that mimic natural bone in its strength, flexibility and/or structure 
(Lewandrowski et al., 2000).  Most are calcium composites designed to be resorbed 
within the body over time.  Autografts, allografts and ceramics and the rationale, benefits 
and drawbacks of choosing them are discussed next. 
 
Autograft 
 Autograft bone is harvested from a different site on the patient and is the “gold 
standard” for bone grafting procedures as it bypasses any risk of rejection or transfer of 
disease.  Autogenous bone acts as a scaffold by providing a template of collagen type I 
and bone minerals that are osteoconductive.  Osteoconduction is the ability to support the 
ingrowth of capillaries, perivascular tissue and osteoprogenitor cells into an implant.  
Osteoinduction is the ability to elicit cells from the surrounding areas.  Stem cells that are 
recruited can then differentiate into osteoblasts.    Thus, in autogenous bone grafts, 
progenitor stem cells are supplied along with the autograft and are responsible for 
osteogenesis.   
The iliac crest is most often chosen as the harvest site for autografts owing to the 
volume and quality of bone available.  It is important to note that even though bone 
harvested from a patient’s iliac crest or ribs transfers progenitor stem cells, their 
osteogenic capability is quickly depleted as most of the cells do not survive the transplant 
(Betz, 2002).  In light of this mortality rate of osteoprogenitor cells, cell proliferation ex 
vivo followed by implantation into a host site (either onto a synthetic scaffold or laden 
onto synthetic carriers) is a possible solution. This would circumvent the problem of low 
numbers of osteoprogenitor cells transplanted into the defect site, by ensuring that large 
numbers of progenitor cells are placed into the defect along with the synthetic material 
thus, exerting their full osteogenic effect. This fundamental idea forms the basis for the 
experimental results presented in my thesis. 
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Disadvantages to using autografts include morbidity due to procuring the 
autograft from another site on the body, increased surgery time and possibility of 
complications (Linovitz and Peppers, 2002).  Acquiring an autograft is also problematic 
as there might be a limited availability of bone in children or in elderly patients, 
especially if a large amount is needed to treat a large critical sized defect (Linovitz and 
Peppers, 2002). 
 
 
Allograft 
An allograft is a bone obtained from another person that is transplanted into the 
patient.  Allografts can be perceived as an alternative to autografts as they do not come 
with donor site complications and morbidity.  Another advantage might be obtaining an 
unlimited supply for the treatment of that one patient.  Allograft bone is processed to 
remove all cells by freezing, freeze-drying or treating with chemicals in order to cut 
down on the risk of infectious agents.  It is important to note that such processing does 
not completely eliminate the possibility of an infection occurring (Gunzburg and 
Szpalski, 2002).  A study looking at 1146 femoral heads for bone bank donation, showed 
unexpected disease in 8% of the bone out of which three bones contained undiagnosed 
bone tumors.  At least four cases to date have been noted where HIV virus was 
transmitted into patients from fresh frozen allografts used, but not from freeze-dried 
bone.  Allograft processing treatments are harsh as they not only rid the donor bone of 
osteogenic cells but they also alter the mechanical properties of the bone (Szpalski and 
Gunzburg, 2002).    There is up to 50% reduction of mechanical strength of bone.  
Rehydrating freeze-dried bone on the other hand, results in cracks which further decrease 
the strength of the graft by almost half (Szpalski and Gunzburg, 2002). Further, the FDA 
has expressed concern over prions being transported in musculoskeletal tissue in 
transplants (Betz, 2002). High cost for obtaining allograft bone as well as variations in 
quality, are factors to consider in the course of allograft procurement and use (Meadows, 
2002).  
 
Ceramics 
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Ceramics or synthetic bone grafts can be used either in conjunction with 
autografts to extend or bolster an autograft, or be used as bone void fillers in bony 
defects.  The use of calcium phosphate-based ceramics has prevailed in dentistry since 
the early 1970’s and their use has been incorporated in orthopaedics since the 1980’s 
(Gruntovskii et al., 1991;Capanna et al., 1991).  The most common forms used are tri-
calcium phosphates (TCP) and hydroxyapatite (HA) whose stochiometry is based on 
bone mineral.  TCPs are considered highly biocompatible.  When these synthetic 
materials are placed next to host bone, osteoid is directly deposited on the surfaces of 
these ceramics, if soft tissue growth is absent.  Once the osteoid mineralizes, the new 
bone can undergo remodeling (Vaccaro, 2002).  Synthetic ceramic materials obviously do 
not provide a supply of osteogenic cells such as those found in autografts.  Neither do the 
ceramics have a bountiful supply of growth factors to induce bone formation.  Both of 
these hurdles can be overcome by seeding the ceramics with osteoprogenitor cells and 
growth factors to fabricate an osteoconductive scaffold or filler.  The added advantage is 
that ceramics are available in an unlimited supply and do not cause added complications 
due to their retrieval from another site.  They do not pose the danger of transmitting 
diseases or eliciting immune responses.   
Estimates show the synthetic bone grafts are used only in 10% of bone graft 
procedures due to the perception that they are inferior.  Nevertheless, this  perception is 
changing (Meadows, 2002).  It is possible that using the synthetic bone grafts in 
conjunction with cells and growth factors might eradicate the inferiority of ceramics.  In 
addition, with the shortage of allografts and the related risk of disease and rejection and 
autograft problems of donor site morbidity and quantity limitations, synthetic ceramics 
might be the way to go.  
 
Ceramic bone void fillers as ‘carriers’ 
 Synthetic bone void fillers are becoming common in spinal surgeries as bone graft 
extenders (Meadows, 2002).  Bone void fillers are commonly used alone in particulate or 
morsel form.  If combined with osteoinductive growth factors and progenitor stem cells 
for osteogenesis, the construct itself becomes a material that is osteoconductive. Such 
studies with human adult mesenchymal stem cells are only just beginning to be carried 
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out and are discussed later.  Some data with animal osteoprogenitor stem cells being 
seeded onto ceramics already exists (Arnold et al., 2002;Cancedda et al., 2003).  Seeding 
the ceramics with a high concentration of cells and allowing them to proliferate and/or 
differentiate on the ceramic prior to implanting can possibly overcome the obstacle that 
autogenous bone grafts face.  This obstacle involves a high mortality rate of 
osteoprogenitor cells due to hypoxia, or washing away the few cells present in the area, 
during surgical manipulations and the irrigation of the wound site.   
Studies have demonstrated that rat marrow stromal cells seeded onto 
poly(propylene fumarate)/beta-tricalcium phosphate (PPF/beta-TCP) composites in vitro 
are able to attach, proliferate and differentiate into osteoblasts (Peter et al., 2000).  
Another study seeded human, mesenchymal stem cells (hMSCS) onto a tricalcium 
phosphate bone void fillers and compared them to the hMSCS seeded onto autografts 
(Fredericks et al., 2004).  Experiments carried out in vitro and in vivo in rabbit segmental 
defects showed that tricalcium phosphate fillers exhibited a high functionality as implants 
due to the their structural properties, and the cells ability to infiltrate the scaffold.  The in 
vivo comparisons showed that the tricalcium phosphate scaffolds were a potential 
alternative to autografts (Fredericks et al., 2004).  Also, bone marrow derived, rabbit 
mesenchymal stem cells seeded onto tricalcium phosphate scaffolds,  have shown 
potential to repair critical cranial defects in rabbits (Bo et al., 2003).  After twelve weeks, 
defects repaired with mesenchymal cells showed healing only on the margins of the 
defect while defects repaired with tricalcium phosphate exhibited bone ingrowth absent 
in the middle of the defect.  When mesenchymal stem cells and tricalcium phosphate 
scaffolds were combined, extensive bone filling in the defects was seen with degradation 
of the scaffold (Bo et al., 2003).   
A recent study by Harris and Cooper (2004) compared the osteogenic potential of 
bone marrow-derived, culture-expanded hAMSC adhering to different scaffolds 
composed of various calcium phosphates.  These calcium phosphates included 
combinations of bovine bone-derived apatite, calcium carbonate-derived apatite, and two 
kinds of hydroxyapatite/tri-calcium phosphate combinations.  When implanted into the 
dorsum of SCID mice for five weeks, the scaffolds exhibited marked differences in their 
ability to support osteoinduction in vivo.  The study stated that the induction of hAMSCs 
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along the osteoblastic pathway might depend partly on the local microenvironment 
established by the scaffold, as well as with interactions with the host.  Similar studies 
have not been carried out with hAMSC seeded onto ChronOSTM Granulat, ChronOSTM, 
and VitossTM, neither in vitro nor in vivo.   
   In my research, three types of porous tri-calcium phosphates were evaluated.  
These bone void fillers are currently used in bone grafting procedures.  I used MG-63 
cells, an osteosarcoma cell line that is commonly used in osteoblast and 
osteoblast/biomaterial research (Martin et al., 1995;Martin et al., 1996;Lincks et al., 
1998;Boyan et al., 2001;Scheven et al., 2002;Amaral et al., 2002).  I also used human 
adult mesenchymal stem cells obtained from the posterior iliac crest of a consenting 
adult.  These cell types were used to evaluate cell interactions with the bone void fillers 
and their feasibility in bone tissue engineering.  All three kinds of bone void fillers and 
two cell types are discussed below, before presenting my research objectives and 
hypotheses.  
 
Porous Tri-calcium Phosphates (TCPs) 
 Tri-calcium phosphates have been used in orthopaedic and dental applications for 
over two decades and have established a safety record as bone void fillers in both these 
fields (McAndrew et al., 1988).  Their chemical formula is Ca3[PO4]2.  They resorb 
rapidly, and they are prone to osteoclastic resorption and remodeling.  By six weeks most 
of the scaffold gets resorbed within the body.  In a study carried out in canine cylindrical 
metaphyseal defects that were repaired with b-TCP ceramics alone, the newly formed 
bone was histologically, radiologically and mechanically comparable to adjacent original 
bone at 12, 24 and 52 weeks (Vaccaro, 2002).  TCPs are mainly used to fill defects alone, 
or along with autografts, at sites where compression forces mainly act on bone (Szpalski 
and Gunzburg, 2002). 
VitossTM 
VitossTM, a commercial b-TCP resorbable ceramic is a porous material that is 
manufactured by Orthovita (Malvern, PA).  The product is marketed as a cancellous bone 
void filler.  The product is available as blocks, cylinders, morsels and putty 
(http://www.orthovita.com/products/vitoss).  The manufacturers do not recommend its 
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use in critical defects when used by itself, but no data are available on its use when 
seeded with bone progenitor cells and expanded and differentiated as an ex vivo culture.    
The physical structure of VitossTM is similar to cancellous bone with 
approximately 90% porosity and 90% interconnectivity in the pores.  The average 
diameter of the particles is 100 nm which is small enough for osteoclastic digestion in the 
remodeling phase of bone healing (Betz, 2002).  The ceramic has a larger surface area 
when compared to conventional TCPs and allows for faster and more complete resorption 
(Lane and Bostrom, 1998).  Due to its high porosity, the material has a low density.  The 
pore sizes range from 1-1000 mm.  The larger pores allow for new bone ingrowth and the 
smaller pores cause the wicking of cells, growth factors and nutrients into and through 
the scaffold (Szpalski and Gunzburg, 2002). Studies carried out on canine erythrocytes 
show that the porous material can hold three times its own volume in blood, bone marrow 
or cells. Thus, communication and bone ingrowth can occur.  Currently the ceramic is 
used as a bone void fillers and X-rays/radiographs have shown that when implanted into 
patients to treat spinal fusions, 100% of patients show good consolidation of the bone 
five to seven months post-operatively (Meadows, 2002).   The rate of resorption of the 
ceramic is 76% at six weeks and close to 86% at twelve weeks when evaluated using 
radiographs (Linovitz and Peppers, 2002).   
ChronOSTM Granulat & ChronOSTM 
Two other commercial ceramics evaluated in my research are manufactured by 
Mathys Medical (http://www.mathysmedical.com).    The two forms of ChronOS differ 
in pore size distributions.  ChronOSTM has a lack of nanoporosity when compared to 
ChronOSTM Granulat due to differences in sintering temperatures employed during 
manufacturing.  ChronOSTM Granulat also has a more defined pore size distribution and 
therefore, a higher nanoporosity as the manufacturers claim.  (Refer to figure 1 for 
scanning electron micrographs showing microstructure comparisons).   
The manufacturers of ChronOS claim that complete substitution by living bone 
takes between 6 to 18 months.  Treatment is indicated for patients with degenerative bone 
diseases, scoliosis, fractures, spine instabilities and vertebrectomies.  The ceramic bone 
void filler is also used for filling sites after autologous harvest from the iliac crest or from 
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the vertebra.  The bone void fillers are marketed in different forms such as cylinders, 
blocks and morsels.   
 
 
 
 
 
 
 
 
Table 1: Physical properties of VitossTM, ChronOS TM Granulat and ChronOS TM 
 
 Chemical 
Structure  
Particle Size  Porosity Pore 
Width 
 
Nanoporosity 
 
VitossTM 
b-TCP 0.71-1.4mm 90% 1-1000mm abundant 
ChronOS TM 
Granulat 
b-TCP 0.71-1.4mm - 100-500 
mm 
abundant 
ChronOS TM b-TCP 
 
0.71-1.4mm 60% 100-500mm none 
 
Table 1: Ceramic bone void filler properties collected from manufacturer provided 
information.  Data obtained from manufacturer websites: 
http://www.orthovita.com/products/vitoss and http://www.mathysmedical.com. 
 b-TCP=b  Tri-calcium Phosphate.  Data not known is marked with a (-).   
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Figure 1: Scanning electron micrographs of bone void fillers.  Bone void fillers 
include VitossTM (A, B), ChronOSTM (C, D) and ChronOSTM Granulat (E, F).  The 
macrostructure of the morsels (A, C, E) with a scale bar of 2 mm, as well as the 
microstructure of the surface of the ceramic (B, D, F) with a scale bar of 50mm is shown.  
SEMs show that ChronOSTM ceramic shows a relative lack of nanoporosity with fused 
grains (D).  (Courtesy of Phil Campbell, Carnegie Mellon University). 
 
A B 
C D 
E F 
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MG-63 Cells 
 A number of osteoblast cell lines and osteoblast precursor cell lines are used in 
the study of bone development, physio logy and bone-tissue engineering.  The MG-63 cell 
line is derived from a human osteosarcoma (isolated from a 14 year old boy) (Heremans 
et al., 1978).  When induced to differentiate with 1,25-dihydroxyvitamin D3 (1,25D3), 
they express increased alkaline phosphatase activity and secrete osteocalcin (Franceschi 
and Young, 1990).  Another point to note is that the MG-63 cells differ from osteoblasts 
in that they do not mineralize their extracellular matrix upon addition of osteogenic-
inducing media but express all other markers of differentiation.  Also, in a study that 
evaluated these cells and another osteosarcoma cell line, both cell lines showed adhesion 
or differentiation characteristics similar to those of human osteoblast- like cells (Clover 
and Gowen, 1994).  The MG-63 cells exhibit features of an undifferentiated osteoblast 
and express increased alkaline phosphatase activity when they are induced to differentiate 
(Clover and Gowen, 1994).  The MG-63 cell line cannot be used for in vivo applications 
in humans, but are a useful in vitro model to assess attachment, proliferation and 
differentiation similar to that of osteoblasts.  More attention was focused on the 
interactions of hAMSC with the bone void fillers, as hAMSC hold the possibility of 
being used in vivo in bone regeneration applications in the future.    
  
Human adult mesenchymal stem cells 
Human adult mesenchymal stem cells (hAMSC) can be isolated from the bone 
marrow and are multipotent, progenitor cells.  hAMSC have the ability to differentiate 
into a number of cell types in vitro including osteoblasts, chondrocytes, adipocytes, 
myoblasts, tendon and ligament cells (Pittenger et al., 1999;Caplan et al., 1998).  In a 
study using culture-expanded, cryopreserved human MSCs implanted in severe combined 
immunodeficiency disease (SCID) mouse models, osteogenic potential of the hAMSC 
was noted.  Six weeks into implantation bone formation via histology was noted and gene 
expression analyses of implanted cells revealed no expression of bone sialoprotein in 
undifferentiated cells and expressed in differentiated cells at three weeks (Cooper et al., 
2001).  hAMSC can be directed to go down the osteoblast lineage in the presence of 
osteogenic supplement (OS).  Under this culture condition, the hAMSC are able to 
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mineralize their matrix (Jaiswal et al., 1997).  The addition of OS (100 nM 
dexamethasone, 10 mM b-glycerophosphate, and 0.05 mM ascorbic acid-2-phosphate) 
induce the cells to attain an osteoblastic morphology (Bruder et al., 1997).  
Dexamethasone is a synthetic steroid that induces differentiation, ascorbic acid allows for 
collagen cross- linking and b-glycerophosphate assists in mineralization (Bruder et al., 
1997).  hAMSC can possibly be seeded onto ceramic bone void fillers and this can bring 
large numbers of multipotent progenitor cells into bone defects.  This combines the 
structural support of the bone void fillers along with the osteoinductive capabilities of 
hAMSC, in order to aid in the faster healing of bone. 
 
Significance 
 The main goals of bone tissue engineering are focused towards healing of bone 
that mimics natural healing.  Currently, this includes using scaffolds of autologous bone, 
allogeneic bone or synthetic ceramics.  Synthetic ceramics, such as those currently used 
as bone void fillers can offer the advantage of being used in conjunction with 
osteoprogenitor cells.  This method offers the advantage of being able to place la rge 
numbers of cells directly into a wound site or onto a tissue-engineering scaffold.  Thus, 
the osteoinductive stem cells from bone marrow can be concentrated and then delivered 
to graft sites, in such bio-hybrid constructs.  These carriers could significantly aid in bone 
tissue engineering if they prove to be capable of sustaining attachment, proliferation, and 
differentiation of hAMSC and could theoretically reduce bone healing times 
significantly.    
For examples, a construct of ultraporous b-TCP VitossTM can possibly be used as 
a carrier for human adult mesenchymal stem cells (hAMSC).  These hAMSC, isolated 
from the bone marrow of a patient, can be seeded onto the ceramic.  hAMSC can be 
cultured ex vivo to densely populate the ceramic prior to its implantation into the defect.  
It is not known whether hAMSC can attach, proliferate and differentiate into osteoblasts 
on VitossTM or the two kinds of ChronOSTM ceramics and is the major aim of my 
research.   
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PROPOSED RESEARCH 
 
Hypotheses 
1) MG-63 cells will attach, remain viable on, proliferate and differentiate on   
     VitossTM, ChronOSTM Granulat and ChronOSTM. 
2) Human adult mesenchymal stem cells will attach, remain viable on, proliferate and   
     differentiate on VitossTM, ChronOSTM Granulat and ChronOSTM. 
 
Specific Objectives: 
The specific objectives of my thesis include: 
1) Determine whether VitossTM, ChronOSTM Granulat and ChronOSTM bone void fillers  
     are cytotoxic to MG-63 cells and human adult mesenchymal stem cells. 
2) Determine whether MG-63 cells will attach and proliferate on VitossTM, ChronOSTM  
    Granulat and ChronOSTM bone void fillers. 
3) Determine whether human adult mesenchymal stem cells will attach and proliferate on 
     VitossTM, ChronOSTM Granulat and ChronOSTM bone void fillers. 
4) Determine whether MG-63 cells will differentiate into osteoblasts on    
     VitossTM, ChronOSTM Granulat and ChronOSTM bone void fillers. 
5) Determine whether human adult mesenchymal stem cells will differentiate into 
     osteoblasts on VitossTM, ChronOSTM Granulat and ChronOSTM  bone void fillers. 
 
MATERIALS AND METHODS 
Cell culture 
MG-63 osteosarcoma cell line  
 The osteosarcoma MG-63 cell line was obtained from Carnegie Mellon 
University’s Bone Tissue Engineering Center (BTEC) cell culture collection.  Cells 
obtained were at passage numbers 90-93.  Cells were cultured at 37°C with 5% CO2 and 
90% humidity in T-75 tissue culture flasks (Corning 430641).  Cells were maintained in 
F-12/MEM supplied by CMU that was supplemented with 10% fetal bovine serum (FBS; 
Gibco 10082-139).  MG-63 cells were passaged when subconfluent by trypsinizing to 
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release adherent cells hAMSC (Gibco 25300-054).  Cells used for evaluations were from 
passages 98 to 102. 
 
Differentiation medium of MG-63 cells 
F-12/MEM was supplemented with 10mM b-Glycerophosphate, 100 nM 
dexamethasone and ascorbic acid-2-phosphate  (50mg/mL) and was used as an osteogenic 
supplement (OS) in F-12/MEM with 10% FBS.    
 
Human adult mesenchymal stem cells (hAMSC) 
hAMSCs cryopreserved at passage two (PT-25001) were purchased from Cambrex.  The 
cells are quality tested for proliferation and their ability to differentiate into multiple lineages 
such as osteogenic, chondrogenic, adipogenic, myogenic and tendogenic lineages.  The cells are 
tested to be free of bacteria, yeast, fungi, HIV-1 and Hepatitis B and C.   
 
Mesenchymal stem cell growth medium (MSCGM) 
 Mesenchymal Stem Cell Growth Media (MSCGM) (PT-3001) was purchased 
from Cambrex.  MSCGM is quality tested for the ability to sustain the proliferation of 
hAMSC.  MSCGM is composed of 10% mesenchymal stem cell growth serum 
supplement, 0.05 mg/ml of streptomycin, 0.05 units/ml of penicillin, and 4 mM L-
glutamine in mesenchymal stem cell basal medium. 
 
Osteogenic supplement (OS) differentiation medium 
 Osteogenic supplement (OS) (PT-3002) is tested by Cambrex for the ability to 
induce the differentiation of hAMSC down the osteoblastic lineage pathway into 
osteoblasts.  OS medium contains 100 nM dexamethasone, 10 mM b-glycerophosphate, 
0.05 mM ascorbic acid-2-phosphate, 0.05 units/ml of penicillin, 0.05 mg/ml of 
streptomycin, 4 mM L-glutamine and 9% mesenchymal stem cell growth serum 
supplements. 
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Maintenance of hAMSC 
hAMSC were cultured as suggested by the supplier at 37º C with 5% CO2 and 
90% humidity in T-75 tissue culture flasks (Corning 430641).  hAMSC were passaged 
when sub-confluent using trypsin-EDTA solution (Gibco 25300-054) to release adherent 
cells.  hAMSC used were from passage 3-8.  Cells were fed with MSCGM medium 
warmed to 37ºC. 
 
Passaging of hAMSC 
 hAMSC were passaged when 90% confluent (sub-confluent) by aspirating  the 
MSCGM and washing with 10 ml of Hank’s Balanced Salt Solution (HBSS) (Atlanta 
Biologicals B0041).  The HBSS was then aspirated and 3.5 ml of trypsin-EDTA solution 
(Gibco 25300-054) was added to the cell layer in the flask.  The flask was then gently 
tilted from side to side to ensure contact with the trypsin solution.  The cells were 
incubated at room temperature and observed under a light microscope along with gently 
tapping the flasks to expedite the hAMSC detaching.  Once detached, the flasks were 
allowed to stand on end for a minute to allow cells to drain to the bottom.  Once again, 
3.5 ml of temperature equilibriated MSCGM was added to the flask using a pipette and 
making sure the medium was pipetted over the cell layer surface several times. 
Trypsin was removed by centrifuging at 500 x g for 5 minutes at room 
temperature and removing the supernatant and resuspending the pellet in 6 ml of 
temperature equilibriated MSCGM.  The cells were resuspended using a pipette and the 
resuspension was divided into two new T-75 flasks that contained 15 ml MSCGM.  Cells 
were incubated at 37º C with 5% CO2 and 90% humidity in T-75 tissue culture flasks.   
 
Porous bone-void fillers 
 All three ceramic biomaterials were provided courtesy of Dr. Phil Campbell, 
Bone Tissue Engineering Center, Carnegie Mellon University, who acquired them from 
their manufacturers.  Their properties are listed below: 
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VitossTM 
VitossTM (Lot number 3006007) was used in fine morsel form and the morsels 
were less than 1 mm in length.  The morsel was dry sterilized in an autoclave for 30 
minutes before use. 
 
ChronOS TM Granulat & ChronOS TM 
 ChronOSTM Granulat (Lot number 2922/2037) & ChronOSTM (Lot number 
020701 7-12) were also used in morsel form.  The morsel sizes ranged from 0.7 to 1.4 
mm.  The morsel was in sterilized bottles, and did not need sterilization prior to use. 
    
Cell cytotoxicity testing on bone void fillers 
 As a preliminary step, it was necessary to evaluate whether the ceramic bone void 
fillers would be cytotoxic to the MG-63 cells and the hAMSC.  Therefore, LIVE/DEAD 
staining using the Cytotoxicity Assay Kit (Molecular Probes, L-3224) was used to 
quantify the number of live and dead cells on coverslips, after they had been subjected to 
media that was conditioned (pre-soaked) in 1gm quantities of ceramic for five days.   
Pre-weighed sterile 15 ml conical tubes were used to hold 1gm quantities of 
ceramic bone void filler that were dispensed using a sterile spatula in the hood.  Five ml 
of either F-12/MEM or MSCGM were added to the tubes and incubated for five days in 
the cell culture incubator for MG-63 and hAMSC growth, respectively at a temperature 
of 37ºC with 5% CO2 and 90% humidity.   
Media was added to 15ml conical tubes without any bone void fillers as an un-
conditioned media control. After 5 days of incubation, 1:5, 1:10 and 1:15-fold dilutions 
of the conditioned media were carried out in their respective media types, along with 
using the original conditioned media. 
 Two mls of either F-12/MEM or MSCGM were added to 6 well plates and glass 
cover slips that were sterilized in ethanol were placed in them.  MG-63 cells and hAMSC 
in low passage and at 70% subconfluency were trypsinized from their T-75 flasks and 
added to the 6-well plates along with 2ml of corresponding media. 
 The cells were allowed to attach overnight and 1ml media was aspirated off the 
coverslips in the 6 well plates using a glass pipette, the following day.  Unconditioned 
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media, conditioned media and conditioned media dilutions were added to the cells on 
coverslips and allowed to incubate for another day. 
 Cell cytotoxicity was then evaluated by scoring live and dead cells by staining the 
coverslips with the Live/Dead Viability Cytotoxicity Assay Lot (Molecular Probes, L-
3224).  The media was aspirated off the coverslips and three washes with PBS were 
carried out.  The cells on the coverslips were stained as directed with the 2mm calcein 
AM for live cells and 4mm ethidium homodimer-1 for dead cells.  Ten random areas were 
counted on each coverslip and assessed for viability by calculating the total percentage of 
live and dead cells visualized by fluorescent microscopy.  
     
Cell seeding on bone void fillers 
Sterile bone void fillers were stored at room temperature and aliquoted into 12- or 24-
well plates using an ethanol-sterilized micro-spatula.  1 ml of media was added to the well plates 
prior to adding the bone void fillers.  Approximately 25 mg of bone void filler, equal to two 
scoops of the micro-spatula, was measured out.  Approximately 50,000 cells/ml, 100,000 
cells/ml or 250,000 cells/ml in media were added on top of the bone void fillers and the plate 
was gently shaken.  One extra ml of media only was added to each well.  The plates with cells 
and bone void fillers were then incubated at 37°C, 5% CO2 and 90% humidity as a static culture. 
 
Washing away unattached cells on bone void fillers post-seeding 
 One day after seeding, the contents of each well were transferred to parallel plates 
using a P-1000 pipette with a cut tip to accommodate the size of the pieces of 
biomaterial.  This was to ensure that only the cells attached to the bone void fillers were 
evaluated and not cells that had attached to the bottom of the well plates.  Care was taken 
to maneuver the morsels as gently as possible in one step so as not to crush them and to 
reduce the possibility of transferring cells from the bottom of the well plate.  After 
transfer, the medium was aspirated and replaced with a fresh vo lume of 1 ml medium. 
For cell feeding, the medium was aspirated off every 3 days and replaced with fresh 
medium. 
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Attachment and proliferation of cells on bone void fillers 
 MTT Stain 
 In order to qualitatively assess the attachment and proliferation of MG-63 cells 
and hAMSC on bone void fillers, approximately 250,000 MG-63 cells/25 mg bone void 
filler/2 ml media per well and 100,000 hAMSC/ 25 mg bone void filler/2 ml media per 
well were seeded.  Unattached cells were washed away the following day and at the 
appropriate time points,  the contents of wells were transferred to centrifuge tubes using a 
P-1000 pipette with a cut tip.  On assessment days 1 and 6 post-seeding, MTT (5mg/ml) 
was directly added to the centrifuge tubes in 0.1 ml volumes in 1.0 ml media.  MTT {3-
[4,5-Dimethylthiazol-2-yl]-2,5-diphenyltetrazolium bromide; Thiazol blue} (Sigma M-
5655) stain is a water-soluble tetrazolium salt that is cleaved and converted to a purple 
insoluble formazan precipitate, in the presence of cellular dehydrogenase activity.    
Samples were incubated for 1 hr at 37°C, 5% CO2 and 90% humidity.  After an hour, the 
reaction was terminated by washing the samples in the centrifuge tubes three times with 
1ml PBS.  Samples were then shaken out into a mini-petri dish, allowed to air dry, and 
viewed under a dissection scope.  The presence of intense blue staining on the bone void 
fillers represents viable MG-63 cells and hAMSC attached on the ceramics.  
 
Scanning electron microscopy (SEM) 
Samples of bone void fillers seeded with cells were washed in PBS and fixed in 
2.5% gluteraldehyde in PBS.  The samples were then washed 3 times with PBS, fixed in 
1% osmium tetroxide for at least 30 minutes.  Samples were then washed 3 times with 
de-ionized water and dehydrated through an ethanol series (50, 70, 80, 90, 100, 100, 
100%) and critical point dried (Pelco CPD2).  Samples were mounted on a glass slide 
with rubber cement, gold-coated using a sputter coater (Pelco SC-6) and viewed with a 
Hitachi 2460 scanning electron microscope at an accelerating voltage of 5kV or 15kV. 
Digital images were captured at varying magnifications.  Samples for SEM were 
processed and imaged by Amy Loveland and Christa Heyward from Duquesne 
University. 
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LIVE/DEAD stain 
 The LIVE/DEAD Viability/Cytotoxicity Assay Kit (Molecular Probes, L-3224) 
was used to evaluate the presence of live and dead cells on the bone void fillers and 
provide a qualitative assessment of cell viability.  The 3-D structure of the morsels 
prevented from making a complete quantitative assessment, as cells on all surface and all 
pores could not be visually quantified in this manner.  Nevertheless, a qualitative 
assessment was carried out. 
Samples were removed from culture and transferred to microcentrifuge tubes on 
days 1, 3 and 6 post-seeding, using a P-1000 pipette and a pipette tip cut to a wide bore.  
Samples were washed three times with 1 ml PBS and were then stained as directed by the 
supplier with 2 mM calcein AM for live cells and 4 mM Ethidium homodimer-1 (EthD-1) 
for dead cells in PBS.  Samples were then incubated for 30 minutes at room temperature.  
After incubating, the samples were washed with 1 ml PBS, and wet mounts were 
prepared using PBS on a microscope slide with a coverslip suspended on a bridge made 
of coverslips.  Live and dead cells were imaged by fluorescent microscopy (Nikon 
Eclipse microscope fitted with a Diagnostics Instruments, Inc. digital camera [model 
2.3.1]) and captured with image capture using QED Camera Standalone imaging software 
[v1.6a30].  Images were then processed using Adobe Photoshop software. 
  
DAPI Stain 
 4’, 6-diamidino-2-phenylindole, dihydrochloride (DAPI) was used to stain the 
nuclei of cells attached to the bone void fillers and thereby assess the qualitative 
attachment and proliferation of MG-63 cells and hAMSC.   On days 1, 3 and 5/6 post 
seeding, samples were removed from the wells to microcentrifuge tubes using a P-1000 
pipette and a wide bore pipette tip, and washed three times with 1ml PBS before fixing 
for 10 minutes at room temperature with 4% paraformaldehyde in PBS.  The amount of 
paraformaldehyde used was just enough to cover the morsels in the microcentrifuge tube.   
Following fixation, samples were washed four times with 1ml PBS.  DAPI (0.6 mg/ml in 
PBS) was added to each sample in a volume that was enough to cover all the morsels and 
allowed to incubate for ten minutes at room temperature.  Samples were then washed four 
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times with 1ml PBS and wet mount samples were prepared in 50% glycerol in PBS.  Cell 
nuclei on biomaterials were viewed by fluorescent microscopy (Nikon Eclipse 
microscope fitted with a Diagnostics Instruments, Inc. digital camera [model 2.3.1]) and 
captured with image capture using QED Camera Standalone imaging software [v1.6a30].  
Images were then processed using Adobe Photoshop software. 
 
 CyQUANT Assay 
 The CyQUANT assay (Molecular Probes, C-7026) was used to quantitatively 
assess the relative number of cells attached to the bone void fillers.  The CyQUANT GR 
dye exhibits strong fluorescence when bound to cellular nucleic acids and is a good 
indicator of cell attachment on bone void fillers after the cells have been lysed in 
samples.  The fluorescence is measured on a fluorescent plate reader and is an indicator 
of number of cells attached.  
For VitossTM and ChronOSTM, the contents of each well were transferred to 
microcentrifuge tubes using a P-1000 pipette with a wide bore pipette tip.  After transfer, 
the medium was aspirated and the samples stored at -80°C.  On the day of the assay, the 
tubes were subjected to a thaw/freeze/thaw cycle in order to lyse the cells.  200 mL of 
CyQUANT GR dye/Cell Lysis Buffer (Molecular Probes, C-7027) was prepared as 
directed and was added to each microcentrifuge tube and incubated at room temperature 
for 2-3 minutes.  Triplicate samples from each microcentrifuge tube were the pipetted 
into a 96-well microtitre plate (FisherBrand 12-565-501) and the fluorescence was 
measured using a fluorescent plate reader (TECAN Spectrafluor plate reader) and results 
were plotted and analyzed using Microsoft Excel.  A standard curve of known cell 
numbers versus CyQUANT fluorescence was plotted. 
 
Cell differentiation in differentiation media 
MG-63 cell differentiation into osteoblast-like cells 
 One week after MG-63 seeding (and subsequent washing/transfer into new well 
plates), the F-12/MEM was aspirated and osteogenic supplement (OS) medium for MG-
63 cells was added.  Differentiation of MG-63 cells was assessed qualitatively by alkaline 
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phosphatase histochemical staining on days 7, 14 and 21 post addition of OS medium, 
with controls (medium with no OS).   
 
hAMSC differentiation into osteoblasts 
 One week after hAMSC seeding (and subsequent washing/transfer into new well 
plates) of hAMSCs, the MSCGM media was aspirated and OS- medium specific for 
hAMSC induction into osteoblasts was added.  Differentiation of hAMSC was assessed 
qualitatively by alkaline phosphatase histochemical staining on days 7, 14 and 21 post 
addition of OS medium, and compared to controls with no OS.  Quantitative evaluations 
of alkaline phosphatase activity assessed by a protein assay were carried out for days 7, 
14 and 21 post-seeding, with or without the presence of OS media. 
 
Alkaline phosphatase histochemical stain 
 Alkaline phosphatase histochemical stain (Sigma 85L-3R) was used to 
qualitatively detect the presence of alkaline phosphatase activity of cells seeded onto 
bone void fillers.  On the appropriate days, samples were taken with a P-1000 pipette 
with a wide bore pipette tip, and were transferred to microcentrifuge tubes.  They were 
then washed three times with PBS, fixed in 80% methanol/20% citrate working solution 
for one minute, and then washed four times with distilled water (Gibco 15230-170).  
Citrate working solution was prepared by mixing 1 ml of citrate concentrate solution 
(Sigma 85-4C) and 49 ml of distilled water.   Stain was then added, with incubation in the 
dark at room temperature for two hours.  Stain components included: Fast violet B 
capsule (12mg/capsule) (Sigma 85-1) and 2 ml napthol AS-MX phosphatase alkaline 
solution (Sigma 85-5) made upto 50ml in distilled water.  Following incubation, the stain 
was aspirated off and the samples were washed three times with 1ml PBS, allowed to dry 
for a few minutes and viewed under a stereo microscope.  Digital images were captured 
using Spot Basic Imaging software and processed with Adobe Photoshop. 
 
Alkaline phosphatase biochemical assay 
 Samples of were taken on days 14 and 21 post addition of OS medium.  The cells 
were cultured in MSCGM (for hAMSCS) and F-12/MEM (for MG-63s) a week prior to 
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adding OS media.  Samples were removed from well plates and transferred to 
microcentrifuge tubes using a P-1000 pipette and a wide bore pipette tip. The medium in 
the centrifuge tubes was aspirated, and the samples were washed with 1 ml PBS and 
aspirated. Another 500 mL of PBS was added to each tube, spun down and cell lysates 
were stored frozen in 250mL of PBS after 250 mL supernatant was removed.  The samples 
were stored in a -20°C.  
To prepare cell lysates, samples were removed and thawed at 37°C for 15 
minutes, and then re-frozen at –80°C for 15 minutes and thawed again at 37°C.  This 
freeze/thaw cycle was then repeated. Fifteen mL samples of the cell lysate were added in 
quadruplicate to wells in a 96-well flat microtiter plate (FisherBrand 12-565-501) 
containing 100mL water (Gibco 15230-162), 35mL of PBS, and 50mL of ABC Buffer.  
ABC Buffer is comprised of equal amounts of 1.55M 2-amino-2-methyl-1-propanol 
(Sigma A9879), 20mM p-Nitrophenol Phosphate Stock (Sigma 104-0), and 10mM MgCl2 
(Sigma M1028).  Standards (p-Nitrophenol;  Sigma 104-1) were prepared by serial 
dilution in water.  The plates were covered in foil and incubated at 37°C for 1 hour.  The 
reactions were terminated with the addition of 50mL of 1M NaOH to each well.   
  The amount of alkaline phosphatase activity in the cell lysate was normalized 
using the BCA Protein Assay (Pierce Biotechnology 27225).  15 µL extract (in PBS 
giving a total volume of 50 µL) was incubated with 50 µL BCA working reagent.  
Absorbance was read at 405nm on a Bio-Rad Model 3550 Microplate Reader.  Protein 
was estimated using bovine serum albumin to prepare a standard curve.  The cell lysate 
absorbances were then inserted into the best-fit line equation from the standard curve. 
 
Statistics 
Comparisons of numerical data as means representing multiple measurements 
over time were analyzed for statistical differences using two-tailed t-tests for pairwise 
comparisons. Statistically significant differences were determined in all cases as having 
p<0.05. 
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RESULTS 
 
 My approach in evaluating the attachment, proliferation, and differentiation of 
MG-63 cells and hAMSC on bone void fillers is outlined by the following diagram. 
 
 
Figure 2:  Flow Chart of Experimental Design 
 
 
Specifically, I sought to evaluate three types of porous tri-calcium phosphates 
namely VitossTM, ChronOSTM and ChronOSTM Granulat that were seeded with either 
human adult mesenchymal stem cells or MG-63 cells.  The attachment, viability, 
proliferation and the ability to differentiate into osteoblasts were evaluated. 
 
Bone void fillers are not cytotoxic to hAMSC & MG-63 cells 
 Both kinds of cells, hAMSC and MG-63 cells, showed high viabilities when 
cultured in un-conditioned media, conditioned media (CM) and subsequent dilutions of 
CM (Table 2).  5 mL media was conditioned by soaking in one gram quantities of bone 
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void filler for five days.  Cells were plated on glass coverslips and cultured overnight in 
the appropriate media and LIVE/DEAD staining was carried out to assess viability.  Ten 
fields were measured on each coverslip and live and dead cells quantified.  Approximate 
number of morsels in each field was 5.  Percentage viabilities for hAMSCs ranged from 
60% to 90% viable cells.  Percentage viabilities for MG-63 cells were greater than 90% 
in all cases.  These results indicate that the bone void fillers were not leaching cytotoxic 
components into the media.   
 
MG-63 cells attach and remain viable on bone void fillers    
 Attachment of MG-63 was assessed one day after seeding by washing 
away unattached cells, staining viable cells with MTT, and imaging stained cells under 
the microscope. 25 mg/well of bone void fillers were seeded with 250,000 cells/well and 
samples were assessed 24 hours post-seeding (Figure 3).  Cell attachment over 1, 3 and 6 
days after seeding was examined via scanning electron microscopy for hAMSC on all 
three bone void fillers.  Scanning electron microscopy (Figure 4) revealed that MG-63 
cells attach to the material surfaces of all three bone void fillers VitossTM, ChronOSTM 
and ChronOSTM Granulat.  In all protocols unattached cells were washed away after the 
second day. The MG-63 cells populated all topographies on the surfaces including 
concavities and pores (Figure 4).   
Attachment and viability were also assessed by DAPI and LIVE/DEAD staining 
showing that MG-63 cells attach and maintain high viabilities up to six days after seeding 
(Figure 7).  The cells densely populated the surfaces as early as Day 1 making individual 
cell counts impossible.  High viability (few dead cells) indicated high survival rates of the 
cells on bone void fillers.  The seeding efficiency of bone void fillers populated with 
MG-63 cells was always 100%, with all morsels of bone void filler being inhabited by 
cells.   
 
hAMSC attach and remain viable on bone void fillers  
Attachment of hAMSC on bone void fillers was assessed on the day of seeding 
(Day 0), by washing away unattached cells within 30 minutes of seeding and estimating 
cell numbers using the CyQUANT assay (Figures 5 and 6).  hAMSC attach to all three 
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kinds of bone void fillers within this 30 minute seeding period.  Scanning electron 
microscopy revealed that human adult mesenchymal stem cells attach to VitossTM and 
ChronOSTM Granulat one day after seeding (Figure 5).  Scanning electron micrographs 
show that cells widely cover the surface of the bone void fillers.  hAMSC densely 
populated bone void fillers as seen by DAPI and LIVE/DEAD stains.  In all cases, 
unattached cells were washed away after the second day and incubation continued.  
Attachment and viability of hAMSC was also assessed with DAPI and LIVE/DEAD 
staining over a 7-day period (Figure 8).  Unattached cells were washed away after the 
second day and incubation continued. hAMSC remain viable on bone void fillers through 
7 days post-seeding.  hAMSC were seeded onto VitossTM, ChronOSTM Granulat and 
ChronOSTM with a cell density of 100,000 cells/ml for up to 7 days.  Percentage viability 
was assessed by counting numbers of live and dead cells in a field of view and dividing 
by total number of cells.  Unattached cells were washed away a day after seeding.  Figure 
9 shows percentage viabilities greater than 90% indicating viable cells on all bone void 
fillers.  Results are representative of two separate independent experiments where 5 
different fields were counted for each time point (approximately 10 morsels were counted 
for each field). 
 
hAMSC proliferate on bone void fillers  
The MTT and DAPI stains did not allow for a complete quantitative assessment 
of cell attachment and proliferation due to the opacity of the bone void fillers hindering 
the ability to count cells on all pores and surfaces of the ceramic.  Images of cells taken at 
one plane would not account for cells attached on other planes.  Thus, the CyQUANT 
assay was used to quantitatively assess the relative number of cells attached to the bone 
void fillers.  In order to assess the proliferation of hAMSC on VitossTM, 20,000 cells/well 
were seeded, and unattached cells were washed away one day later. The CyQUANT 
assay on Days 1 and 4 was used to assess the relative number of cells attached. Because 
unattached cells were washed away a day after seeding, increases in cell number 
represent the proliferation of hAMSC on bone void fillers between days 1 and 4.  Results 
presented in Figure 10 are an average of three independent experiments.   Statistically 
significant differences were seen by day 4 in all three experiments (p<0.0001).  
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In order to assess the proliferation of hAMSC on ChronOSTM and ChronOSTM 
Granulat, 20,000 cells/well were seeded and unattached cells were washing away one day 
later.   The CyQUANT assay on days 3 and 6 was used to assess the relative number of 
cells attached to the bone void fillers. Because unattached cells were washed away a day 
after seeding and prior to measuring, increases in cell number represent the proliferation 
of hAMSC on bone void fillers between days 3 and 6.  Results represented in Figure 11 
are of triplicate samples from one experiment.  Statistically significant differences were 
observed between days 3 and 6 indicating cells proliferation (p<0.0001for both types of 
ChronOS). 
 
MG-63 cells attached to bone void fillers express alkaline phosphatase activity 
(ALP) in response to an osteogenic supplement  
Alkaline phosphatase activity (ALP) is a phenotypic marker for differentiating 
osteoblasts.  The differentiation of MG-63 cells into osteoblast cells was assessed by ALP 
histochemical staining at 7, 14 and 21 days after addition of OS and compared to ALP 
activity in control cells.  MG-63 were seeded at a density of 250,000 cells/well on all 
three types of bone void fillers. Cells on all three of the bone void fillers show an intense 
red staining when cultured in the presence of OS in contrast to control cells cultured in 
the absence of OS (Figure 12).  
  
hAMSC attached to bone void fillers express alkaline phosphatase activity (ALP) in 
response to an osteogenic supplement  
Histochemical stain for alkaline phosphatase activity: The differentiation of 
hAMSC into osteoblast cells was assessed by ALP histochemical staining at 7, 14 and 21 
days after addition of OS and compared to ALP activity in control cells.  hAMSC were 
seeded at a density of 100,000 cells/well on all three types of bone void fillers. The 
appearance of intense red staining of cells in OS medium is a qualitative indication of 
ALP activity due to the differentiation of hAMSC into osteoblasts on bone void fillers.  
hAMSC on bone void fillers in control media (no OS added) showed little red staining 
suggesting low ALP activity, presumably due to lack of differentiation of hAMSC into 
osteoblasts (Figure 13). 
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In order to test whether hAMSC were present on the control bone void filler 
morsels, both OS+ and control samples were stained with DAPI (Figure 15). DAPI 
staining was seen on the morsels which indicates that after more than 3 weeks in culture, 
cells were still attached to the bone void fillers and in some places completely covered 
the surfaces (arrows), or still showed individual nuclei (Figure 15).   
Biochemical assay for alkaline phosphatase activity: After 2 and 3 weeks of 
treatment with OS, samples of hAMSC were taken to determine the ALP activity of cells 
attached to bone void fillers by a biochemical assay.  ALP activity in the cells incubated 
with OS medium was higher than the controls after 2 and 3 weeks of treatment on all 
bone void fillers (Figure 14).  Although ALP activity was higher in OS treatments when 
compared to controls, statistically significant differences were seen for VitossTM 
(p=0.002) and ChronOSTM (p=0.004) after 3 weeks of treatment.   
 
CONCLUSIONS 
1) VitossTM, ChronOSTM Granulat and ChronOSTM bone void fillers do not exert a    
    cytotoxic effect on MG-63 cells and human adult mesenchymal stem cells. 
2) MG-63 cells attach and proliferate on VitossTM, ChronOSTM Granulat and ChronOSTM    
     bone void fillers. 
3) Human adult mesenchymal stem cells attach and proliferate on VitossTM, ChronOSTM  
     Granulat and ChronOSTM bone void fillers. 
4) MG-63 cells express alkaline phosphatase activity on VitossTM, ChronOSTM Granulat   
     and ChronOSTM bone void fillers. 
5) Human adult mesenchymal stem cells express alkaline phosphatase activity on   
    VitossTM, ChronOSTM Granulat and ChronOSTM bone void fillers. 
 
DISCUSSION 
Human adult mesenchymal stem cells (hAMSC) can be isolated from the bone 
marrow and are osteoprogenitor cells.  hAMSC have the ability to differentiate into a 
number of cell types in vitro that include osteoblasts, chondrocytes, adipocytes, 
myoblasts, tendon and ligament cells (Caplan et al., 1998).  The advantage of using these 
cells allows bringing large numbers of multipotent progenitor cells into bone defects 
A B  
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combining the structural support of the bone void fillers along with the osteoinductive 
capabilities of hAMSC.  In theory, this can aid in the faster healing of bone as compared 
to healing times achieved by use of bone void fillers alone.  Thus, a simple procedure 
such as harvesting bone marrow from the patient could provide the progenitor cells that 
could be expanded and differentiated into osteoblasts, to be implanted back into the 
patient.  It is important to note that this aspect of regenerative medicine is not completely 
without risks such as infection. 
Along with mesenchymal stem cells, multipotent adult progenitor cells can be 
harvested from a patient.  These can differentiate into a number of lineages including 
neurectodermal, mesodermal and endodermal cell types and have been isolated not only 
from bone marrow but also muscle and brain tissue (Jiang et al., 2002).  Thus, either of 
these cell types is a suitable candidate for ex vivo expansion and re-implantation once 
differentiated, to aid in bone regeneration.  Another cell type with potential uses in bone 
tissue engineering are embryonic stem cells as they are a self-renewing population of 
cells that can give rise to any lineage in the body including endodermal, mesodermal and 
ectodermal lineages.  They are derived from the inner cell masses of blastocysts and 
therefore pose an ethical debate as they can either be obtained from discarded embryos at 
IVF clinics or derived by somatic cell nuclear transfer by cloning (Bishop et al., 2002).  
The use of human adult mesenchymal stem cells in tissue engineering bypasses the 
ethical dilemma that comes with the use of embryonic stem cells. 
It is already known that calcium and phosphate based scaffolds induce bone 
formation when implanted alone, depending on the animal model used (Ripamonti, 
1999), and thus, this justifies the seeding of hAMSC onto bone void fillers to hasten the 
healing.  Comparative studies have already shown that HA and ß-TCP based ceramics are 
proven to be applicable for bone regeneration therapies when implanted by themselves 
(Uemura et al., 2003;Schnurer et al., 2003).  A considerable number of studies also exist 
on the use of various hydroxyapatite or tricalcium phosphate ceramics seeded with cells 
as hybrid constructs to aid in bone healing both in vitro and in vivo (Kubler et al., 
2004;Hicok et al., 2004;Yudoh and Nishioka, 2004;Kim et al., 2004;Harris and Cooper, 
2004;Mankani et al., 2004;Wang et al., 2004;Velich et al., 2004). Studies with rat 
marrow-derived, cultured mesenchymal cells introduced into porous calcium-phosphate 
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ceramics have showed strong osteogenic potential, with bone forming in vivo in the pore 
regions of ceramics as early as 2 wk after implantation (Goshima et al., 1991).  Similar 
studies with goat marrow stromal cells seeded onto porous biphasic calcium phosphate 
ceramics showed that significant regeneration was achieved in iliac, critical sized defects 
in goats at nine weeks (Kruyt et al., 2004).  A recent study by Marcacci et. al. showed 
that bone marrow-derived osteoprogenitor cells seeded onto HA scaffolds and implanted 
into three patients with large bone defects, achieved bone regeneration (Marcacci et al., 
2003).  Studies in immunocompromised animals are the next step towards bone healing 
in vivo.  An interesting animal model would be the implantation of hAMSC on bone void 
fillers implanted into rat calvarial defects for bone regeneration.     
In this study, I evaluated the abilities of MG-63 cells and human adult 
mesenchymal stem cells to attach, proliferate and differentiate into osteoblasts after 
seeding onto clinically relevant bone void fillers.  These included VitossTM, ChronOSTM 
and ChronOSTM Granulat.  In order for the bone void fillers to be useful for bone 
regeneration in vivo, it was necessary to demonstrate that the cells are able to attach, 
remain viable and proliferate in vitro and are expandable.   
The MG-63 cell line was used as an initial assessment to evaluate whether cells 
would survive, attach and proliferate on the bone void fillers.  Owing to the fact that the 
cell line is an osteosarcoma cell line, it cannot be implanted in vivo and was thus 
evaluated as a preliminary, qualitative assessment of cells cultured in the bone void filler 
in vitro environment.  Most of the applications for using MG-63 cells in studies assess the 
cells as a preliminary investigation to see whether they attach to certain biomaterials, 
remain viable on the biomaterials or express morphological or biochemical characteristics 
similar to those of osteoblasts (Massaro et al., 2001;Lee et al., 2004;Amaral et al., 
2002;Kim et al., 2002).  It was proposed that seeding hAMSC onto bone void fillers in 
vitro and allowing them to attach, proliferate and differentiate into osteoblasts would 
improve the efficacy of these bone deformity treatments. Thus, I sought to improve the in 
vitro aspect by seeding ceramic bone void fillers with hAMSC and evaluating their 
attachment, proliferation and differentiation into osteoblasts. 
Autologous mesenchymal stem cells seeded on a scaffold of 65% hydroxyapatite 
and 35% tri-calcium phosphate can induce new bone formation and heal critical sized-
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segmental defects in dogs (Bruder et al., 1998).  b-TCP has also been incorporated into 
constructs with fibrin glue, PLGA polymer and human periosteal cells, thereby 
supporting the proliferation and increased alkaline phosphatase activity of the cells over 
time (Arnold et al., 2002).  My research is similar to these studies in that the focus is the 
study of biomaterials made of b-TCP and their interactions with hAMSC, as potential 
bio-hybrid constructs. 
Methods to assess attachment and proliferation of cells on bone void fillers.   
In order for bone void fillers to be useful for bone treatments in regenerative medicine in 
vivo, it needed to be shown that cells are able to attach, remain viable and proliferate on 
the ceramics.  This ex vivo expansion and successful culturing of cells is in order to have 
a larger number of cells per bone void filler per use.  The possibility of bone void fillers 
exerting a cytotoxic effect on the cells was ruled out by carrying out cytotoxicity testing.  
Both cell types showed high percentage viabilities in the presence of conditioned media 
(CM) and  subsequent dilutions of CM.  The MG-63 cells showed greater than 90% 
viabilities and this might be due to the MG-63 cell line being a hardy, osteosarcoma cell 
line with a high proliferation rate.  hAMSC also had high percentage viability rates 
ranging from 60%-90%.  Percentage viabilities for hAMSC could also have depended on 
the pH of the media changing during the incubation period and thereby causing an effect 
on the cells.  Even though this was not tested, the color of the media changed as it was 
incubated with the bone void fillers for the five day period. 
The attachment and proliferation of both kinds of cells was evaluated by MTT 
stain, scanning electron micrographs, DAPI and LIVE/DEAD stain to qualitatively assess 
their attachment and proliferation on days 1, 3/4, and 5 post-seeding.  The LIVE/DEAD 
stain does not allow for a complete 3-D quantitative assessment of cell proliferation due 
to the opacity of the bone void fillers hindering the ability to count cells on all pores and 
surfaces of the ceramic.  The 3D structure requires focusing through different planes in 
order to image cells on certain planes one at a time.  Thus, quantification of hAMSC on 
bone void fillers was carried out using the CyQUANT assay which measures cell 
numbers by the binding of the CyQUANT GR dye to nucleic acids of hAMSC.  Thus, 
attachment and proliferation of hAMSC was quantitatively assessed using the CyQUANT 
assay for hAMSC seeded onto bone void fillers and showed that hAMSC not only 
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attached to all three bone void fillers with a half hour of seeding, the hAMSC also 
demonstrated proliferation on bone void fillers with statistically, significant increases in 
cell numbers over time on all three bone void fillers (p<0.0001 in all cases).  (Figures 10-
11).  Initially, the MTT stain was used to assess the number of cells attaching as well as 
proliferating on the ceramics.  While it did stain cells that had attached to the bone void 
fillers, the assay was not sensitive enough to measure the proliferation quantitatively.  
The results varied highly possibly due to a light scatter effect from the biomaterial and all 
efforts were abandoned.   
  Past studies have shown that hAMSC attach and proliferate when loaded onto 
hydroxyapatite/tricalcium phosphate matrices (De Kok et al., 2003).  Scanning electron 
micrographs (SEM) showed that both MG-63 cells as well as hAMSC can attach onto the 
surfaces as well as pores of all three bone void fillers.  SEM studies examining of 
attachment and proliferation of osteoblasts and fibroblasts on a copolymer poly(lactide-
co-glycolide (PLAGA) scaffold showed that cells grew in concentric patterns and had an 
ability to fill (100-250 mm) pores (Borden et al., 2002).  A colonization of pores by the 
hAMSC was also noted but enough repetitions were not done of SEM to notice a 
colonization pattern.  My research along with the SEM results showed that hAMSC are 
able to attach and proliferate on tricalcium phosphate bone void fillers.  Table 2 and 
Figures 3, 5, 6, 8-11 show that hAMSC will attach to the three bone void fillers and 
increase in number over time.  Viability of the hAMSC on bone void fillers was greater 
than 90% as determined by LIVE/DEAD viability stain (Figure 2).  Unattached cells 
were washed away and incubation continued.  The results show that this high viability 
percentages of hAMSC were maintained for all three time-points including day 6.  In a 
study by Manso et. al. hAMSC seeding efficiencies were assessed to be 65%±25% when 
seeded onto HA coated silicon wafers (Manso et al., 2002).  The percent of bone void 
fillers seeded with hAMSC was 100% in all cases with all the morsels of bone void filler 
colonized by many cells.  My results therefore show a high seeding efficiency of hAMSC 
on ß-TCP based VitossTM, ChronOSTM and ChronOSTM Granulat bone void fillers. 
  MG-63 cells also populated with high viabilities all topographies on the material 
surfaces including concavities and pores. Large numbers of live cells that fluoresced 
green showed up as intense green as cell boundaries blended and prevented individual 
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cell recognition.  The MG-63 cells were seeded with a density of 250,000 cells/well onto 
bone void fillers and stained with LIVE/DEAD stain and seemed to densely populate the  
surfaces making individual cell counts impossible.  This gave a visual representation of 
high percentage viabilities (few dead cells) and thereby high survival rates of the cells on 
bone void fillers (Figure 7). A study using a scaffold of chitosan sponges and HA/ß-TCP 
can support the attachment and proliferation of MG-63 cells (Zhang and Zhang, 2002).  
In my study, it is shown that MG-63 cells can attach to ß-TCP morsels and remained 
viable on their surface and within their concavities.   
  A study on surface roughness of materials and cells indicates that MG-63 cells 
do not attach well to smooth surfaces (Kieswetter et al., 1996).  Another study using a rat 
osteosarcoma cell line has shown that both proliferation and differentiation significantly 
decrease on hydroxyapatite surfaces that have 30% microporosity.  The researchers claim 
this microporosity leads to increased surface roughness (Rosa et al., 2002).  In a study 
that evaluated surface roughness of titanium disks, as roughness increased, MG-63 cells 
expressed higher alkaline phosphatase in response to Vitamin D3 (Boyan et al., 1998).  In 
the light of these studies, further research on the interactions of MG-63 cells with the  
surface topographies of these different bone void fillers is warranted.   
It was interesting to note that even though the bone void fillers had varying 
topographies and varying porosities, the cells attached on the surfaces as well as inside 
the concavities (Figure 16).  The cells seemed to prefer the insides of the ‘caves’ more 
but more studies need to be done before that can be concluded definitively.  Studies have 
also shown that seeding sheep bone marrow stromal cells onto 3D scaffolds of 
bioceramic composites followed by implantation into tibial defects results in bone 
formation not only on the outer surface of the implant but also within the bioceramic’s 
pores (Cancedda et al., 2003).  Another study indicated that increases in surface 
roughness might produce an environment conducive for bone regeneration by enlisting 
cytokines and growth factors (Kieswetter et al., 1996).  Kieswetter’s study predicts that 
increase in surface roughness increases differentiation.  A study of human osteoblast cells 
showed that as the surface roughness decreased on a metallic surface, more proliferation 
was seen (Anselme et al., 2000).  Further studies need to be carried out on proliferation 
rates of hAMSC on these bone void fillers.  Even though the hAMSC proliferated on 
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bone void fillers, the proliferation was not as much of the osteosarcoma cells, the MG-
63s (which have the high doubling times).  These comparisons between hAMSC and 
MG-63 cells have not been quantified though and studies of proliferation of especially 
hAMSC seeded with the same seeding density on different ceramics will be interesting.  
A CyQUANT comparison of MG-63 rate of proliferation to the rate of proliferation of 
hAMSC can also be carried out, but was not the main purpose of this study. 
Other methods of quantifying attachment and proliferation of cells include 
incorporating radioactive nucleotides into cells during proliferation and examples is the 
use of [3H] thymidine (Mosmann, 1983).  Since the CyQUANT assay provides a 
convenient means to accurately quantify the DNA and RNA of the cells and thereby 
estimate increasing cell numbers, I did not attempt the radioactive techniques of 
proliferation measurement.  An improvement in CyQUANT experiments would be to use 
an RNAse enzyme to degrade the RNA in the samples, thereby allowing the assay to be 
sensitive to the DNA only. 
 
Differentiation of cells on bone void fillers .  The osteogenic differentiation of 
purified, culture-expanded hAMSC has been assessed in a study by Jaiswal et. al. in 
tissue culture wells and plates (Jaiswal et al., 1997).  In this study, the differentiation of 
hAMSC into osteoblasts, when treated with osteogenic supplement (OS) was 
demonstrated by a significant increase in alkaline phosphatase activity (ALP), expression 
of osteocalcin, formation of a mineralized matrix and changes in osteoblastic cell 
morphology. 
In my research, I evaluated the differentiation of hAMSC seeded on bone void 
fillers, by assessing ALP activity as a phenotypic marker of differentiation into 
osteoblasts.  ALP as a biochemical marker for osteogenesis was measured for both MG-
63 cells, as well as hAMSCS.  ALP activity assessed via histochemical staining revealed 
intense staining for both cell types when cultured with OS on bone void fillers.  Control 
cultured showed little or no intense staining.  For hAMSC, these results indicate 
differentiation into osteoblasts, based on this one phenotypic marker. These results were 
qualitatively similar to the results obtained by Jaiswal et. al.(Jaiswal et al., 1997).  
Takamizawa et. al. showed that ascorbic acid-2-phosphate when supplemented into 
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culture media of MG-63 cells, showed an increase in expression of osteoblast 
differentiation markers such as ALP activity and collagen synthesis (Takamizawa et al., 
2004).  These results were similar to the increased ALP activity assessed by 
histochemical stain on the MG-63 cells treated with OS media.  Another study also 
showed that  MG-63 cells exhibit increased ALP levels in the presence of ascorbic acid-
2-phosphate and dexamethasone when cultured on tissue-culture plastic (Franceschi and 
Young, 1990), similar to my results.  A study by Zhang and Zhang shows that a scaffold 
of HA/ß-TCP chitosan sponges supports not only the attachment and proliferation of 
MG-63 cells, but also their differentiation into osteoblasts as evaluated by ALP activity 
(Zhang and Zhang, 2002).  Their results are comparable to my results with MG-63 cells 
seeded on bone void fillers, as the ceramic fillers not only support the attachment of these 
cells but allow high viability and support differentiation of these cells into osteoblasts.  
Thus, the MG-63 cells express this single phenotypic marker (ALP) for differentiation 
into osteoblasts.   
ALP activity for hAMSC was also assessed using a biochemical assay.  My 
results showed approximate 2-fold increases (OS versus control) after a period of three 
weeks in osteogenic supplement for one experiment.  In the Jaiswal study, 7-fold 
increases were noted in hAMSC plated onto tissue culture plastic in one representative 
experiment over a two week time period (Jaiswal et al., 1997).  The fold increase between 
OS and no OS samples of hAMSC seeded onto bone void fillers in my research were not 
as high, but in all cases, increases were seen in ALP activity in OS samples for week 2 
and week 3 post-addition of OS (Figure 14).  Statistically significant increases were also 
seen in ALP activity of hAMSC seeded on VitossTM and ChronOSTM for week 3 post-
addition of OS.   
  Another assay that would have been useful in determining the differentiation of 
cells into osteoblasts would have been to measure the expression of osteocalcin, 
osteonectin or osteopontin by RT-PCR techniques or immunochemical methods.  These 
assays would provide further evidence for hAMSC differentiation into osteoblasts.  
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The future of synthetic ceramics in bone tissue engineering   
Synthetic ceramics such as VitossTM, ChronOSTM Granulat and ChronOSTM, 
which are currently used as bone void fillers in humans can offer the advantage of being 
used in conjunction with osteoprogenitor cells. Thus, osteoinductive stem cells from bone 
marrow can be concentrated and then delivered to graft sites on these bone void filler 
composites, providing an ideal bone graft substitute material.  The total number of 
hAMSC present in the patient is inversely correlated to factors such as age and the 
systemic disease state of the body, as well as site of extraction (Majors et al., 1997).  
This, along with a possible decrease in healing times for bone defects with these 
Biohybrid constructs, furthers the need for culture and proliferation of hAMSC on bone 
void fillers in vitro. These carriers can significantly aid  in bone tissue engineering as they 
are capable of sustaining attachment, proliferation, and differentiation of hAMSC.  Using 
these synthetic bone void fillers for bone grafts in conjunction with cells and growth 
factors might eradicate the perceived inferiority of ceramics.  Also, with the shortage of 
allografts, their risk of disease and rejection, problems of donor site morbidity and 
limited quantities associated with autografts, synthetic ceramics might be a better 
alternative.   
 
FUTURE DIRECTIONS 
More studies are necessary in order to assess bone void fillers as a vehicle for 
delivery of hAMSC into bone defects.  My results evaluating the attachment, 
proliferation and differentiation of hAMSC on VitossTM, ChronOSTM and ChronOSTM 
Granulat show great promise for their use.  The analysis of further osteoblastic 
phenotypical markers such as calcium deposition is impossible due to the beta tri-calcium 
phosphate nature of the bone void fillers themselves, but measurement of osteocalcin, 
osteonectin or osteopontin mRNA would be useful. 
Another interesting study would be to conduct studies of convex surfaces of pores 
when compared to concave surfaces and to investigate which surfaces are preferred by 
the hAMSC.  Observations made during LIVE/DEAD staining showed more cells 
colonizing the insides of concave pores.  More studies need to be done in order to show 
whether the cells have a preference and such characteristics can be used to design better 
38 
biomaterials and better hybrid therapies for bone healing.  Thus, in-depth studies of 
surface undulations and its effect on cell attachment, proliferation and differentiation are 
needed.  Further SEM studies could be carried out to evaluate how far into the center of 
the bone void filler, the cells attach.  It is already known that highly porous scaffolds play 
a critical role in cell seeding, proliferation, and new 3D-tissue formation (Liu and Ma, 
2004).  Previous studies have shown though that cells prefer a concave surface for de 
novo generation of bone (Ripamonti, 1999).  Such studies have not been carried out using 
hAMSC.  A study by Borden et. al. carried out an in vitro evaluation of human 
osteoblasts seeded onto porous microcarriers made of PLAGA scaffold and showed that 
the structure was capable of supporting the attachment and proliferation of cells 
throughout its pore system (Borden et al., 2003).  Immunofluorescent staining of actin 
showed that the cells colonize within the pore system.  Another study by Zhang et. al. 
showed that MG-63 osteoblast cells attached to a composite calcium phosphate scaffolds, 
proliferated on the scaffold surface, and migrated onto the pore walls (Zhang and Zhang, 
2002). It would also be interesting to see whether the hAMSC are able to migrate off the 
surface of the bone void fillers.  This could potentially mean that the hAMSC were able 
to migrate off and populate a larger 3D scaffold that served as a matrix to promote tissue 
regeneration.  In the light of these bio-hybrid construct recommendations to aid in bone 
healing it is also important to note that there are several aspects to the implanted cell-host 
interaction that need to be addressed before the mechanisms underlying such stem cell 
therapies are used widely. These include the host immune response to implanted cells, 
understanding homing mechanisms that guide delivered cells to a site of injury, and most 
importantly, differentiation of implanted cells under the influence of local signals (Barry, 
2003). 
Further experiments could include the culture of hAMSC on bone void fillers in 
some kind of spinner culture, possibly with a continuous supply of media.  The spinner 
culture could encourage cells to attach onto all facets of the bone void fillers and the 
continuous supply or perfusion of media could promote proliferation and/or 
differentiation.  It is also possible that spinner culture would prevent cells from attaching 
and the agitation would instead, knock cells off the bone void fillers.   Other studies 
involving the use of bone morphogenetic proteins (BMPs) added to the culture media can 
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be carried out with hAMSC seeded on bone void fillers to see whether osteoblast and 
bone formation is affected.    Studies have been carried out with other calcium-phosphate 
based ceramics loaded with BMPs in a collagen sponge and implanted into cranial 
defects in rabbits, exhibit enhanced bone formation (Ruhe et al., 2004).  Needless to say, 
implantation of bone void fillers seeded with hAMSC, into a critical sized defect in an 
immunocompromised animal, such as the rat, is the next logical step to see whether bone 
is regenerated.  Since the bone void fillers are already in clinical use by themselves, the 
risk of an immune response does not exist.  The next step for this research would be to 
carry out the in vivo studies in animal models to study bone regeneration. 
 
40 
 
 
 
 
  
Unconditioned 
Media 
Conditioned 
Media 
(CM) 
 
1:5 
CM 
 
1:10 
CM 
 
1:15 
CM 
hAMSC      
VitossTM * 83% 73% 83% 90% 90% 
ChronOSTM 
Granulat 
 
90% 
 
85% 
 
57% 
 
78% 
 
92% 
ChronOSTM 100% 97% N.D. 92% 96% 
MG-63      
VitossTM * 99% 99% 98% 99% 97% 
ChronOSTM 
Granulat 
 
94% 
 
93% 
 
94% 
 
90% 
 
97% 
ChronOSTM 99% 99% 99% 99% 99% 
 
Table 2: Percent viabilities of hAMSC and MG-63 cells on bone void fillers - 
cytotoxicity testing.  Percentage viabilities (Total live cells/Total number of cells) of 
hAMSC and MG-63 cells when cultured in un-conditioned media, conditioned media 
(CM) and subsequent dilutions of the CM.  Viabilities represent the mean of ten fields.  
Cells were cultured overnight in the corresponding media types and LIVE/DEAD 
staining was carried out to assess viability.  Ten fields were examined for each coverslip 
and live and dead cells quantified by LIVE/DEAD staining.  Results for bone void fillers 
marked with a * are the average of two independent cytotoxicity tests. Data marked N.D. 
was not determined due to contamination.  All the experiments were performed once.  
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                                                                                               Day 0      1                                             
                                               
                                                                                                Seed     MTT Stain 
 
Figure 3: MG-63 cells attach to bone void fillers as assessed by MTT staining.  Bone 
void fillers were seeded with 250,000 cells/2 ml media/25 mg bone void filler and 
samples were taken on day 1 for MTT staining. Attachment of MG-63 cells on bone void 
fillers was visualized using MTT stain stained dark blue.  Seeding efficiency (% bone 
void fillers with cells/total bone void filler morsels) was 100%.  
ChronOSTM 
ChronOS 
GranulatTM 
VitossTM 
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Fig 4: MG-63 cells attach to bone void fillers.  Scanning electron microscopy shows 
MG-63 cells on the surfaces of all three bone void fillers, VitossTM (A, D), ChronOSTM 
(B, E) and ChronOSTM Granulat (C, F) on day 6 after seeding. 250,000 cells/2 ml 
media/25 mg bone void filler were seeded.  The MG-63 cells populated all topographies 
on the ceramic surfaces including concavities and pores on the bone void fillers.  Images 
in the top panels are at a lower magnification with a scale bar of 500 µm and the bottom 
panels are at a higher magnification with a scale bar of 200 µm. 
VitossTM                              ChronOS TM                  ChronOS TM Granulat 
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Fig 5: hAMSC attach to bone void fillers.  Scanning electron microscopy revealed that 
human adult mesenchymal stem cells attach to VitossTM (A, C) and ChronOSTM Granulat 
(B, D) one day after seeding.  40,000 cells/2 ml media/25 mg bone void filler were added 
to each well.  hAMSC populated all topographies on the ceramic surfaces including 
concavities and pores on the bone void fillers.  Images on the top panel are at a lower 
magnification with a scale bar of 100 µm and the bottom panel images are at a higher 
magnification with a scale bar of 50 µm.   
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                                                                                              Day 0                                  
 
                                                                                              Seed      
                                                                                              Wash/CyQUANT Assay 
 
 
 
Fig 6:  hAMSC attach to bone void fillers - CyQUANT Quantification.  The 
CyQUANT assay was used to assess the relative numbers of cells attached to the bone 
void fillers on Day 0 (seeding day) based on fluorescence.  Unattached cells were washed 
away within 30 minutes of seeding.  hAMSC were seeded on VitossTM, ChronOSTM and 
ChronOSTM Granulat bone void filler with a cell density of 20,000 cells/2 ml media/25 
mg bone void filler in each well.  Results obtained were the mean ± standard error of the 
mean of three independent experiments.  For ChronOSTM and ChronOSTM Granulat the 
results shown are the mean ± standard error of the mean of quadruplicate samples for one 
experiment.   
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                                                                   Day 0    1                    3                            5 
 
                                                                   Seed   Wash/       LIVE/DEAD   LIVE/DEAD 
                                                                            Transfer            & DAPI          & DAPI 
 
Figure 7: MG-63 cells attach and remain viable on VitossTM, ChronOS TM and 
ChronOS TM Granulat - DAPI and LIVE/DEAD stain.  250,000 MG-63 cells/2 ml 
media /25 mg bone void filler were seeded in each well and showed attachment and high 
viabilities through 5 days post-seeding.  Unattached cells were washed away on day 1 
after seeding.  DAPI stained cellular nuclei blue and LIVE/DEAD stained live cells green 
and dead cells red, thereby allowing for a semi-quantitative assessment of live/dead 
ratios.  Seeding efficiency (% bone void fillers with cells/total morsels) was 100%.  
Morsels shown are representative images. 
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                                                Day 0      1                          3                           6 
 
                                            Seed   Wash/Transfer       LIVE/DEAD          LIVE/DEAD 
                                                                                             & DAPI      & DAPI 
Figure 8: hAMSC attach and remain viable on bone void fillers.  Attachment and 
viability of hAMSC on VitossTM (VIT), ChronOSTM Granulat (CH-G) and ChronOSTM 
(CH) assessed on 1, 3, and 6 days of seeding with LIVE/DEAD and DAPI stain.  100,000 
hAMSC/2ml media/25 mg bone void filler were seeded per well.  Live hAMSC are 
indicated by green fluorescence and dead hAMSC fluoresce red, allowing for a semi-
quantitative assessment of live/dead ratios.  DAPI stained cellular nuclei blue.  Seeding 
efficiency (% bone void fillers with cells/total bone void filler morsels) was 100%. 
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Figure 9: Percent viabilities of hAMSC on bone  void fillers.  hAMSC were seeded 
onto VitossTM, ChronOSTM Granulat and ChronOSTM with a cell density of 100,000 
cells/2 ml media/25 mg bone void filler in each well for up to 6 days.  Unattached cells 
were washed away a day after seeding.  Percent viability was assessed by counting 
numbers of live and dead cells in a field of view and dividing by total number of cells.  
Results are means of two independent experiments where 5 different fields were counted 
for each time point, for each experiment.  10 pieces were counted in each field.   
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Figure 10: hAMSC proliferate on VitossTM  
Cellular proliferation of hAMSC seeded on VitossTM with a cell density of 20,000 cells/2 
ml media/25 mg bone void filler in per well, was assessed between day 1 and day 4 post-
seeding by the CyQUANT assay.  Results are the mean ± standard error of the mean of 
three independent experiments with quadruplicate samples in each experiment.  
Unattached cells were washed away one day after seeding and increases in cell number 
represent the proliferation of hAMSC on bone void fillers.  Means were compared by 
two-tailed t-test.   
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Figure 11: hAMSC proliferate on ChronOS TM and ChronOS TM Granulat.  Cellular 
proliferation of hAMSC seeded with 20,000 cells/2 ml media/25 mg bone void filler in 
each well was assessed between day 3 and day 6 seeding by CyQUANT assay.  Results 
are the mean ± standard error of the mean of quadruplicate samples of a representative 
experiment.  Unattached cells were washed away one day after seeding and increases in 
cell number represent the proliferation of hAMSC on bone void fillers between days 3-6.  
Means were compared by two-tailed t-test.   
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Figure 12: MG-63 cells incubated with an osteogenic supplement (OS) stain positive 
for expression of alkaline phosphatase activity on bone void fillers.  250,000 MG-63 
cells/2 ml media/25 mg bone void fillers, VitossTM (VIT), ChronOS GranulatTM (CH-G) 
and ChronOSTM (CH), were seeded in each well.  On days 7, 14 and 21 post-addition of 
(OS+) or without the addition of osteogenic supplement (OS-) samples were fixed and 
stained for alkaline phosphatase activity.  Representative no OS (OS-) control samples 
are shown for Day 21 and were similar for Days 7 and 14.   
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Fig 13: hAMSC incubated with an osteogenic supplement (OS) stain positive for 
expression of alkaline phosphatase activity on bone void fillers.  Images show 
hAMSC cultured on VitossTM (VIT), ChronOSTM Granulat (CH-G) and ChronOSTM 
(CH).  100,000 hAMSC/2 ml media/25 mg bone void filler were seeded per well.  On 
Days 7, 14 and 21 post-addition of osteogenic supplement (OS) or without osteogenic 
supplement (OS-), samples were fixed and stained for alkaline phosphatase activity.  
Representative control samples are shown for Day 21 and were similar for Days 7 and 14.   
 
52 
 
 
                                   Day 14                                                       Day 21 
 
Day 
0   1                            7 Differentiation assessed à                                   
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Figure 14: hAMSC on bone void fillers express alkaline phosphatase activity in the 
presence of osteogenic supplement (OS).  hAMSC cultured on VitossTM (V), 
ChronOSTM Granulat (CG) and ChronOSTM (C) on day 14 and day 21 post-addition of 
osteogenic supplement (OS+) and controls (OS-).  Results are the mean ± standard error 
of the mean of quadruplicate samples of one experiment.  Means were compared by a 
two-tailed t-test.  Statistically significant differences (p<0.05) between OS and No OS 
treatments are marked with a *.     
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Figure 15: DAPI stain of hAMSC seeded on bone void fillers after staining with 
alkaline phosphatase histochemical stain.  The presence of hAMSC is seen in both OS 
and No OS samples, 3 weeks post-addition of OS.  
54 
 
Figure 16 : LIVE/DEAD stain of hAMSC colonizing insides of pores on bone void 
fillers .  A representative sampling of images shows hAMSC not only colonized the outer 
surfaces of the bone void fillers but also colonized the insides of concave 
depressions/pores found on their surfaces of VitossTM (VIT), ChronOSTM Granulat (CH-
G) and ChronOSTM (CH).  White arrows point to cells inside pores while yellow arrows 
point to cells inside pores that are faintly seen through the other side, i.e. “the back wall 
of the cave”.  
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